The Medicines Co $ 84.9 0 (0%)
MDCO News and Headlines - The Medicines Co
The firm trimmed its Monster Beverage Corp. (MNST) position by 98.66%. The trade had an impact of -4.91% on the portfolio.
The producer energy drinks and other nonalcoholic beverages has a market cap of $36.25 billion and an enterprise value of $35.34 billion.
GuruFocus gives the company a profitability and growth rating of 10 out of 10. The return on equity of 28.26% and return on assets of 22.59% are outperforming
With a new year upon us, we remain in uncharted equity and economic waters. In the US, the current bull run has been the longest on record, as has the ongoing economic expansion. With unprecedented levels of global monetary stimulus, however, questions remain as to how much of the equity market’s rally over the past 10-plus years should be ascribed to central bank liquidity.
Still, for most market participants and observers the 2020 macroeconomic outlook appears positive, buoyed by a number of factors. The Federal Reserve, for example, lowered rates three times in 2019 but more recently indicated
David Einhorn (Trades, Portfolio) on Tuesday reported buying a stake in gene therapy company NeuBase Therapeutics (NBSE) followings its merger with Ohr Pharmaceutical. Neubase also disclosed Greenlight’s involvement in a press release announcing the close of its merger several days earlier on July 12.
Shares of the combined NeuBase tumbled 7.33% to $4.30 in Wednesday trading, and are down 22.5% since they began trading on the Nasdaq Tuesday.
Einhorn agreed to purchase a 9.12% stake in NeuBase immediately after the completion of the merger in a private placement that closed July 15. At an opening share price
Biohaven Pharmaceutical (BHVN)'s plans for a secondary offering of $300 million has given both shareholders and speculators a headache. For one, the offering will dilute the value of existing stockholders’ investment in the Connecticut-based migraine company. Second, it seems to take off the table the long-rumored likelihood that Biohaven might be acquired.
News of the offering has sent the company’s shares down about $20 in the past three weeks, to just more than $44. Prior to the decline, the stock had soared more than 80% from the beginning of the year to early June.
A sale of Biohaven seems
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “March 2019” and All Insider Sales to “$5,000,000+.”
According to these filters, the following are trades from company insiders this week.
Engaged Capital Co-Invest VI-D and Glenn W. Welling, a director and 10% owner, bought a combined 7,949,822 shares of The Hain Celestial Group Inc. (HAIN) for an average price of $20.25 per share on March 7.
The consumer-packaged food company
According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios.
Olin Corp. (OLN) is trading around $30.27 with a price-sales ratio of 0.8, a price-earnings ratio of 8.2 and a forward price-earnings ratio of 11.6. The company has a market cap of $5.06 billion and the stock price has risen at an annualized rate of 5% over the last 10 years.
The company manufactures chlorine, sodium hydroxide and ammunition. The discounted cash flow calculator gives the stock a fair
After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (ALNY) brought the world’s first RNAi treatment, known as Onpattro,Â to market.
Despite this accomplishment, the company did not see a significant jump in its stock following the Food and Drug Administration's approval. In fact, Alnylam is down approximately 6% over the last three months.
Despite the cold market reaction, it is clear Alnylam is promising long term for several reasons. First, RNAi therapies in general show tremendous promise in treating diseases. Second, Alnylam is in the process of
In Thursday trading, L Brands Inc. (LB) lost ground on the heels of the company reporting its financial results for the fourth quarter. The company posted adjusted earnings of $2.11 per share. Revenue increased 7.3% year over year to $4.28 billion. Further, the company beat earnings estimates by six cents and revenue expectations by $100 million.
Looking ahead, the company expects full-year 2018 earnings per share to be between $2.95 and $3.25. For the first quarter, earnings per share are projected to range from 15 cents to 20 cents.
Shares of AmTrust Financial Services Inc. (AFSI) traded higher on news
First Eagle Investment (Trades, Portfolio) is an independent firm with an estimated $97 billion in assets under management. The firm manages a portfolio composed of 334 stocks with a total value of $39.105 billion. In the third and fourth quarters of 2016 the guru bought shares in the following stocks:
Threshold Pharmaceuticals Inc. (THLD)
During the third quarter of 2016, the guru increased the position by 86.75% and in the fourth quarter increased it by 18.73%. The guru holds 9.91% of the stock’s outstanding shares.
It is a biotechnology company engaged in discovery and development of
The All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+” and the duration to “December 2016” and All Insider Sales to “$5,000,000+.”
According to the above filters, the following are trades from company insiders in the past week.
Fredric N. Eshelman, director of The Medicines Co. (MDCO), bought 621,721 shares for $33.77 per share on Dec. 8. Since then, the stock price has dropped by 2.8% to $32.82.
The company has an institutional ownership of 98.67% and insider ownership of 2.29%.
Netflix, Inc. (NFLX)
Shares of Netflix, Inc. (NFLX)Â reached all-time high levels in extended trading Wednesday as the company delivered profit numbers in its quarterly financial results that exceeded analysts' expectations.
For its first quarter 2015, NFLX posted revenues of $1.57 billion, a 23.9% increase year over year, and non-GAAP net income (adjusted for foreign-exchange rate changes since last year) of $48 million, or $0.77 per diluted share, topping the Capital IQ Consensus Estimate of $0.63 earnings per share for the period
NFLX added a record 4.9 million new members globally in the first quarter, against its
First Eagle Fund of America's 4th-Quarter Commentary - GuruFocus.com
|2019-12-10 $ 84.22 (0.08%)|
|2019-12-04 $ 84.1 (0.23%)|
|2019-11-25 $ 83.8 (22.25%)|
|2019-11-15 $ 50.89 (-3.64%)|
|2019-07-17 $ 36.52 (-1.3%)|
David Einhorn's Greenlight Buys NeuBase Therapeutics Stake - GuruFocus.com
|2017-03-30 $ 49.09 (-1.88%)|
First Eagle's Investments of the Last 2 Quarters - GuruFocus.com
|2016-12-12 $ 35.47 (1.78%)|
6 Stocks Traded by Insiders Last Week - GuruFocus.com
|2013-01-21 $ 30.23 (%)|
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS - GuruFocus.com
|2011-03-02 $ 16.69 (-4.03%)|
|2010-11-09 $ 12.13 (-1.62%)|
|2010-05-10 $ 7.54 (4%)|
|2010-05-04 $ 7.36 (-5.03%)|
|2009-11-10 $ 7.67 (%)|
|2009-08-10 $ 8.06 (0.75%)|
|2009-05-11 $ 10.52 (0.48%)|